What were the main governance items approved at the CME Group Inc. Annual Meeting?

The primary governance items approved were the Incentive Plan for Named Executive Officers and the Omnibus Stock Plan. These plans were amended and restated to comply with IRS regulations (Section 162(m)) and included adjustments to plan terms like duration and maximum awards. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor and voted on the election of directors and advisory proposals related to executive compensation.

Were there any significant changes to the executive compensation plans?

Yes, the Incentive Plan for Named Executive Officers was amended to extend its term to May 23, 2022, and the maximum award under the plan was increased to $10,000,000. These changes, along with others, were made to ensure compliance with Section 162(m) of the Internal Revenue Code, which requires shareholder approval of such plans periodically.

How did shareholders vote on the advisory proposals regarding executive compensation?

Shareholders approved, by advisory vote, the compensation of the Company's named executive officers with a significant majority of 'For' votes. Furthermore, shareholders voted in favor of holding such advisory votes on executive compensation on an annual basis.

What was the level of shareholder participation in the Annual Meeting?

Shareholder participation was robust, with approximately 88% of the issued and outstanding shares of Class A and Class B common stock present at the Annual Meeting, either in person or by proxy. This high turnout indicates strong engagement from the company's shareholders.

CME 8-K: Material Agreements & Shareholder Matters

Summary

CME Group Inc. filed an 8-K on May 30, 2017, detailing the outcomes of its Annual Meeting of Shareholders held on May 24, 2017. The primary focus of this filing is the shareholder approval of key governance items, including amendments to executive compensation plans and the ratification of the independent auditor. Notably, the company sought and received shareholder approval for its Incentive Plan for Named Executive Officers and its Omnibus Stock Plan, which were necessary to comply with IRS regulations and included adjustments to the plan terms. The meeting saw a strong shareholder turnout, with approximately 88% of outstanding shares represented. All proposed matters, including director elections, executive compensation advisory votes, and the frequency of future advisory votes on compensation, passed with significant support. The ratification of Ernst & Young LLP as the independent auditor for 2017 was also overwhelmingly approved. This filing provides transparency on shareholder decisions regarding executive compensation structure and corporate governance practices.

Key Highlights

1Shareholder approval was obtained for the Second Amended and Restated CME Group Inc. Incentive Plan for Named Executive Officers, extending its term to May 23, 2022, and increasing the maximum award to $10,000,000.
2The CME Group Inc. Second Amended and Restated Omnibus Stock Plan was also approved by shareholders.
3These plan amendments were primarily to meet requirements under Section 162(m) of the Internal Revenue Code, necessitating shareholder approval every five years.
4Ernst & Young LLP was ratified as the Company’s independent public accounting firm for 2017 with strong shareholder support.
5An advisory vote on the compensation of named executive officers was approved, indicating shareholder confidence in the company's compensation practices.
6Shareholders voted to hold an advisory vote on executive compensation annually.
7A high shareholder turnout of approximately 88% of issued and outstanding shares was recorded at the Annual Meeting.

CME GROUP INC. 8-K Report, Material Agreement (May 30, 2017)

Summary

Key Highlights

Frequently Asked Questions